Mehmet Basaran, MD
Allergy · Westerville, OHNPI 1861499741
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.8% of the total across 461 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,096, 2.2 times the $958 reported in 2019.
Across 461 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$1K
- AstraZeneca$1K
- Regeneron Healthcare Solutions, Inc.$967
- CSL Behring$908
- GSK$641
- Grifols USA, LLC$456
- plus $3K from 27 others
What the payments were for
- Consulting fees$250%
- Food & beverage$7,98796%
- Education$3294%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 81 | $1,221 |
| AstraZeneca | 54 | $1,151 |
| Regeneron Healthcare Solutions, Inc. | 44 | $967 |
| CSL Behring | 49 | $908 |
| GSK | 46 | $641 |
| Grifols USA, LLC | 22 | $456 |
| Amgen(2 entities) | 25 | $263 |
| Octapharma USA, Inc. | 13 | $255 |
| Novartis | 10 | $239 |
| Pfizer | 10 | $205 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $201 |
| Alk-abello, Inc | 10 | $179 |
| Biocryst US Sales Co., LLC | 8 | $170 |
| Blueprint Medicines Corporation | 8 | $162 |
| Optinose US, Inc. | 9 | $156 |
| Genentech USA, Inc. | 9 | $150 |
| ARS Pharmaceuticals Operations, Inc. | 7 | $136 |
| Pharming Healthcare, Inc. | 7 | $124 |
| Kaleo, Inc. | 8 | $113 |
| Covis Pharma GmbH | 6 | $101 |
| Sanofi-aventis U.S. LLC | 1 | $90 |
| LEO Pharma Inc. | 4 | $77 |
| AbbVie | 3 | $74 |
| ADMA Biomanufacturing LLC | 3 | $65 |
| Lilly USA, LLC | 2 | $55 |
| Ionis Pharmaceuticals, Inc. | 3 | $42 |
| GC Biopharma USA, Inc. | 2 | $41 |
| Hikma Pharmaceuticals USA | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Cycle Pharmaceuticals Inc | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
| Eyevance Pharmaceuticals LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy providers in Ohioto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RuconestC1 Esterase Inhibitor, Recomb | 14 | $1,135,503 |
| CinryzeC1 Esterase Inhibitor | 13 | $888,041 |
| XembifyImmune Globulin,gamma(Igg)klhw | 11 | $78,259 |
| Breo ElliptaFluticasone/Vilanterol | 81 | $41,390 |
| Arnuity ElliptaFluticasone Furoate | 69 | $17,206 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $16,220 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $10,472 |
| DuleraMometasone/Formoterol | 13 | $6,514 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 57 | $5,335 |
| Diphenhydramine Hcl | 77 | $5,101 |
| Wixela InhubFluticasone Propion/Salmeterol | 25 | $2,940 |
| Epinephrine | 12 | $2,478 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 85 | $2,054 |
| Montelukast Sodium | 151 | $1,605 |
| Levocetirizine Dihydrochloride | 71 | $1,499 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharming Healthcare, Inc.Ruconest | $124 | $1,135,50314 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Cinryze | $201 | $888,04113 claims |
| Grifols USA, LLCXembify | $456 | $78,25911 claims |
| GSKBreo Ellipta, Arnuity Ellipta, Trelegy Ellipta | $641 | $74,816170 claims |
| AstraZenecaBreztri Aerosphere | $1,151 | $10,47215 claims |
| Hikma Pharmaceuticals USAEpinephrine | $30 | $2,47812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Ohioon file to place this against a meaningful peer group, so we don't.
Other allergy in Westerville
- Roger FriedmanWesterville$155K
- Princess OgboguColumbus$143K
- Kara WadaDelaware$8K
- Asif KhanYoungstown$5K
- Barry LamplBeachwood$5K
- Terri McMillanCincinnati$3K
- Casey CurtisColumbus$2K
- Ronald StraussFairview Park$700
- Gregory WattsCleveland$535
- Gurjit Khurana-HersheyCincinnati$444
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.